Novel 4-aminoquinolines: Synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase, antitubercular activity, SAR, and preclinical evaluation.
Animals
Mice
Aminoquinolines
/ chemical synthesis
Antitubercular Agents
/ chemical synthesis
Mycobacterium tuberculosis
/ drug effects
NAD (+) and NADP (+) Dependent Alcohol Oxidoreductases
/ antagonists & inhibitors
Enzyme Inhibitors
/ chemical synthesis
Tuberculosis
/ drug therapy
Disease Models, Animal
Antitubercular drug candidate
Hit optimization
In vivo activity
InhA
Multidrug-resistant strains
Tuberculosis
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
05 Jan 2023
05 Jan 2023
Historique:
received:
23
08
2022
revised:
25
10
2022
accepted:
03
11
2022
pubmed:
27
11
2022
medline:
6
12
2022
entrez:
26
11
2022
Statut:
ppublish
Résumé
Herein a series of 4-aminoquinolines were synthesized in an attempt to optimize and study the structural features related to LABIO-17 biological activity, a Mycobacterium tuberculosis NADH-dependent enoyl-acyl carrier protein reductase (MtInhA) inhibitor previously identified by a virtual-ligand-screening approach. Structure-activity relationships led to novel submicromolar inhibitors of MtInhA and potent antitubercular agents. The lead compound is 87-fold more potent as enzymatic inhibitors and 32-fold more potent against M. tuberculosis H37Rv strain in comparison with LABIO-17. These molecules were also active against multidrug-resistant strains, devoid of apparent toxicity to mammalian cells and showed favorable in vitro ADME profiles. Additionally, these compounds were active in an intracellular model of tuberculosis (TB) infection, showed no genotoxicity signals, satisfactory absorption parameters and absence of in vivo acute toxicity. Finally, treatment with selected 4-aminoquinoline for two weeks produced bacteriostatic effect in a murine model of TB. Taken together, these findings indicate that this chemical class may furnish candidates for the future development of drug-sensitive and drug-resistant tuberculosis treatments.
Identifiants
pubmed: 36435016
pii: S0223-5234(22)00810-8
doi: 10.1016/j.ejmech.2022.114908
pii:
doi:
Substances chimiques
4-aminoquinoline
GTE5P5L97N
Aminoquinolines
0
Antitubercular Agents
0
NAD (+) and NADP (+) Dependent Alcohol Oxidoreductases
EC 1.1.1.-
Enzyme Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114908Informations de copyright
Copyright © 2022 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.